Brawn Biotech Limited

As of June 30, 2026, Brawn Biotech Limited carries a market capitalization of 61.51M, placing it among publicly traded companies globally. Its enterprise value stands at 61.51M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Brawn Biotech Limited has 3.00M shares outstanding.

As of June 30, 2026, Brawn Biotech Limited trades at a trailing price-to-earnings ratio of 7.01.

These figures are as of June 30, 2026. The EV/Sales ratio of 0.36 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 61.51M versus a market cap of 61.51M, with the gap driven by net debt and cash on the balance sheet.

These figures are as of June 30, 2026.

These figures cover the twelve months ended June 30, 2026. The company generates approximately 23.01M in revenue per employee across its workforce of 7.50, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Brawn Biotech Limited recorded an income tax benefit of -9.39M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -806,000.00 and 8.59M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 21, 2026, Brawn Biotech Limited's stock has gained approximately 31.95% over the past 52 weeks. The 50-day moving average sits at 22.77, while the 200-day moving average is 21.34.

Over the twelve months ended June 30, 2026, Brawn Biotech Limited generated 172.59M in revenue and converted that into 8.59M in net income, yielding earnings per share of 2.93. EBITDA reached -4.56M, while operating income came in at -5.78M.

Over the twelve months ended June 30, 2026, Brawn Biotech Limited posted a gross margin of 14.56, reflecting its pricing power and cost economics. The operating margin of -3.35 and net profit margin of 4.98 provide insight into operational efficiency.